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Summary
Background Adolescents living with HIV face challenges to their wellbeing and antiretroviral therapy adherence and 
have poor treatment outcomes. We aimed to evaluate a peer-led differentiated service delivery intervention on HIV 
clinical and psychosocial outcomes among adolescents with HIV in Zimbabwe.
Methods 16 public primary care facilities (clusters) in two rural districts in Zimbabwe (Bindura and Shamva) were 
randomly assigned (1:1) to provide enhanced HIV care support (the Zvandiri intervention group) or standard HIV 
care (the control group) to adolescents (aged 13–19 years) with HIV. Eligible clinics had at least 20 adolescents in pre-
ART or ART registers and were geographically separated by at least 10 km to minimise contamination. Adolescents 
were eligible for inclusion if they were living with HIV, registered for HIV care at one of the trial clinics, and either 
starting or already on ART. Exclusion criteria were being too physically unwell to attend clinic (bedridden), psychotic, 
or unable to give informed assent or consent. Adolescents with HIV at all clinics received adherence support through 
adult counsellors. At intervention clinics, adolescents with HIV were assigned a community adolescent treatment 
supporter, attended a monthly support group, and received text messages, calls, home visits, and clinic-based 
counselling. Implementation intensity was differentiated according to each adolescent’s HIV vulnerability, which was 
reassessed every 3 months. Caregivers were invited to a support group. The primary outcome was the proportion of 
adolescents who had died or had a viral load of at least 1000 copies per μL after 96 weeks. In-depth qualitative data 
were collected and analysed thematically. The trial is registered with Pan African Clinical Trial Registry, number 
PACTR201609001767322.
Findings Between Aug 15, 2016, and March 31, 2017, 500 adolescents with HIV were enrolled, of whom four were 
excluded after group assignment owing to testing HIV negative. Of the remaining 496 adolescents, 212 were recruited 
at Zvandiri intervention sites and 284 at control sites. At enrolment, the median age was 15 years (IQR 14–17), 52% of 
adolescents were female, 81% were orphans, and 47% had a viral load of at least 1000 copies per μL. 479 (97%) had 
primary outcome data at endline, including 28 who died. At 96 weeks, 52 (25%) of 209 adolescents in the Zvandiri 
intervention group and 97 (36%) of 270 adolescents in the control group had an HIV viral load of at least 1000 copies 
per µL or had died (adjusted prevalence ratio 0·58, 95% CI 0·36–0·94; p=0·03). Qualitative data suggested that the 
multiple intervention components acted synergistically to improve the relational context in which adolescents with 
HIV live, supporting their improved adherence. No adverse events were judged to be related to study procedures. 
Severe adverse events were 28 deaths (17 in the Zvandiri intervention group, 11 in the control group) and 57 admissions 
to hospital (20 in the Zvandiri intervention group, 37 in the control group).
Interpretation Peer-supported community-based differentiated service delivery can substantially improve HIV virological 
suppression in adolescents with HIV and should be scaled up to reduce their high rates of morbidity and mortality.
Funding Positive Action for Adolescents Program, ViiV Healthcare.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
The number of adolescents (aged 10–19 years) with HIV 
globally is growing as more perinatally-infected children 
survive into adolescence.1–3 Adolescents have the highest 
rates of attrition from HIV treatment and care of any 
age group, resulting in higher rates of treatment failure, 
morbidity, and mortality compared with children and 
adults.3–6 In sub-Saharan Africa, which is home to 
85% of adolescents with HIV globally, adolescents are 
the only population with increasing mortality rates.1–3,7 
Of particu lar concern are combined data from east and 
southern African countries showing that only 45% of 
adolescent girls living with HIV are virologically 
suppressed (versus the goal of 73% under UNAIDS 
90-90-90 targets for 2020),8 making them more 
vulnerable to treatment failure and progression to 
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expensive second-line and third-line regimens than 
other age groups.
WHO recommends antiretroviral therapy (ART) for 
all individuals with HIV, irrespective of disease stage or 
CD4-positive T-cell count.9 For adolescents, WHO addi-
tionally recommends community-based interventions to 
support ART adherence and retention in care, while 
acknowledging that the evidence to support this recom-
mendation is weak.9 Few studies have rigorously explored 
the effectiveness of community-based programmes to 
improve the wellbeing and longevity of adolescents with 
HIV, and the current pace of intervention research 
remains inadequate to their needs.1–3,10 Systematic reviews 
highlight the small number of studies done among 
adolescents with HIV, despite this being the age group 
that is in greatest need of interventions to support their 
wellbeing, adherence, and retention in care; these reviews 
recommend prioritisation of further intervention studies 
with adolescents.1,10–12
Optimisation of the public health impact of ART 
among adolescents with HIV will require scalable, 
effective, and cost-effective strategies that provide differ-
entiated support for adolescents with HIV to maximise 
their wellbeing and facilitate their engagement with 
treatment and care. Differentiated service delivery has 
the potential to optimise the effects of ART among 
vulnerable and key populations.1,13,14 Differentiated ser-
vice delivery models simplify and decentralise HIV care 
by adapting services across the care cascade to the 
preferences and expectations of different subpopulations 
of people living with HIV.14
The Zvandiri (meaning “As I am” in Shona) programme, 
which was recommended in 2013 by WHO as a best 
practice programme,15 is a theoretically grounded, multi-
component differentiated service delivery model 
for children, adolescents, and young people with HIV.16 
Zvandiri aims to directly improve the wellbeing of this 
population and strengthen their engage ment with 
services across the HIV prevention and care cascades.16 
In this cluster-randomised trial, we aimed to evaluate 
the effectiveness and cost of the Zvandiri programme in 
relation to clinical and psychosocial outcomes among 
adolescents with HIV in Zimbabwe.
Methods
Study design and participants
The trial design has been described in detail elsewhere.7 
Briefly, we did a cluster-randomised controlled trial in 
public clinics in two rural districts (Bindura and Shamva) 
in Mashonaland Central province, Zimbabwe. Districts 
were selected in consultation with the Ministry of Health 
and Child Care in June, 2015, when it was estimated that 
ART coverage among adolescents with HIV in these 
districts was the lowest in Zimbabwe (about 29%).
Clinics were eligible for inclusion if they were public 
primary care facilities and had at least 20 ado lescents 
in pre-ART or ART registers. Eligible clinics were 
geographically separated by at least 10 km to minimise 
Research in context
Evidence before this study
Adolescents have the highest rates of attrition from HIV 
treatment and care of any age group, resulting in higher rates 
of treatment failure, morbidity, and mortality than that of 
children and adults. We searched PubMed for articles published 
in English between database inception and July 31, 2019, 
using the search terms: “HIV” AND “adolescents” OR “youth” 
AND “HIV treatment” AND “adherence” OR “retention”. 
Systematic reviews of interventions to improve ART adherence 
and retention in care among adolescents with HIV have 
identified specific interventions that show promise, such as 
individual and group education and counselling, financial 
incentives, youth-friendly clinic services, and increased 
accessibility to clinics. However, these reviews also highlight the 
need for additional studies in this subgroup. To date, only 
two trials have shown an intervention to be effective against 
virological outcomes among populations with HIV in 
low-income and middle-income countries in general and 
adolescents with HIV, specifically.
Added value of this study
To our knowledge, this is the first youth-led cluster-randomised 
trial of a multicomponent differentiated service delivery 
intervention focusing on adolescents’ HIV-related and 
psychosocial outcomes. This study adds to the scant evidence 
base for comprehensive interventions for adolescents with 
HIV—a group with disproportionately poor HIV treatment 
outcomes. Notably, our qualitative data highlight the 
importance of improving the broader relational context in 
which adolescents with HIV live in order to support their 
adherence and retention in care.
Implications of all the available evidence
This study adds to the growing body of evidence to support 
WHO’s recommendations for comprehensive, differentiated 
service delivery interventions to support ART adherence and 
retention in care. Our study evaluated the Zvandiri programme 
as delivered in a real-world and resource-constrained setting, 
suggesting the Zvandiri intervention can be feasibly 
implemented in similar settings. Our cost analysis suggests 
incorporating the Zvandiri intervention into current standard 
of care would increase the cost of providing HIV treatment to 
adolescents with HIV in the short term. Policy makers might 
need to invest in these higher costs to avert the health and 
economic consequences of not achieving viral suppression in a 
population likely to require several decades of ART, and in a 
setting with a scarce number of alternative and more costly 
drugs.
For more on the Zvandiri 
programme see https://www.
africaid-zvandiri.org/
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contamination. Adolescents were eligible for inclusion 
if they were living with HIV, registered for HIV care at 
one of the trial clinics, aged 13–19 years, either starting 
or already on ART, able to provide informed assent, and 
their caregiver was able to provide informed consent 
(those aged 18–19 years did not need caregiver consent). 
Exclusion criteria were being too physically unwell 
to attend clinic (bedridden), psychotic, or unable to 
give informed assent or consent. At each clinic, a list 
of potentially eligible participants was generated from 
the pre-ART or ART registers and selected village health 
workers were asked to contact adolescents with HIV 
after receiving training on trial objectives, procedures, 
and importance of maintaining confidentiality.
Ethics approval was granted by the Medical Research 
Council of Zimbabwe and the ethics committees of the 
London School of Hygiene & Tropical Medicine (London, 
UK) and University College London (London, UK). 
Written informed consent from guardians and age-
appropriate assent from participants were obtained 
before enrolment.
Randomisation and masking
Public clinics were the unit of randomisation. Clinics 
were randomly assigned (1:1) to receive either enhanced 
ART adherence support through the Zvandiri programme 
(the Zvandiri intervention group) or standard of HIV care 
(the control group). Imbalance between the groups was 
reduced by matching on district and by using restricted 
randomisation to minimise imbalance in clinic size 
(difference in mean clinic size ≤10). For randomisation, 
we used random-number tables generated in Stata by 
an independent statistician. The data manager had sole 
access to the password-protected randomisation file. A 
public randomisation meeting was held on July 5, 2016.
It was not possible to mask intervention status from 
the field research team, but laboratory staff who assessed 
the primary outcome were unaware of intervention 
status. In addition, statisticians undertaking analyses 
were masked to allocation. We used non-site specific 
study ID numbers on all laboratory and data collection 
forms to maintain masking.
Procedures
At enrolment, all participants completed a questionnaire 
using interviewer-administered, computer-assisted 
personal interviews lasting about 60 min. Sensitive 
questions were self-administered using an audio-
computer-assisted survey instrument. Questionnaire 
domains included socio demographic, socioeconomic, 
medical history (inc luding history of opportunistic 
infections and admission to hospital), HIV testing and 
history of ART use, information on clinic attendances, 
adherence, and psychological wellbeing. On completion 
of the questionnaire, all participants were asked to 
provide a finger-prick blood spot sample for HIV viral 
load testing and to undergo a clinical examination to 
assess WHO stage. All viral load test results were 
returned to the clinic within 3 months (standard 
turnaround time) to guide clinical care in the Zvandiri 
intervention and control groups. Participants were 
assessed by the research team, in addition to their 
routine clinic visits, after weeks 42–60 and 96. At 
the follow-up visits, participants completed another 
questionnaire (shorter than the previous one) that 
covered the same topics as the first, had a blood spot 
sample taken for viral load testing, and had a physical 
examination to allow clinical staging. Programme data 
were collected in the communities receiving the 
Zvandiri intervention and regularly compiled to record 
uptake and attendance at community intervention and 
use of clinical services.
All eligible adolescents attending clinics received ART 
and adherence support, as set out in the Ministry of 
Health and Child Care guidelines.17 For participants in 
the control group, adherence support was provided by 
adult counsellors and nursing staff. After ART initiation, 
these participants were seen every 3 months, with CD4 
monitoring every 6 months. Prescription refills, pill 
counts, and consultations with clinical staff were used to 
measure adherence.
Participants in the Zvandiri intervention group 
received standard care, as determined by the Ministry 
of Health and Child Care, plus the Zvandiri intervention. 
Details of the Zvandiri intervention have been 
published previously.7,16 Briefly, up to three trained and 
supported peer counsellors (community adolescent 
treatment supporters [colloquially known as CATS] who 
are adolescents with HIV aged 18–24 years) at each 
clinic provided adherence coun selling and support at 
clinic visits and through ongoing individualised 
community-based support. All community adolescent 
treatment supporters attended a weekly supervision 
meeting at the clinic with a designated nurse and 
provided each other with peer-to-peer support (through 
a Whatsapp group and via Skype) with oversight from a 
Zvandiri mentor in the district. Up to ten trial 
participants were allocated to a designated community 
adolescent treatment supporter according to their 
residential area and were followed up through text 
messages, phone calls, home visits, and during their 
clinic reviews. The type and frequency of contact was 
determined following assessment of their individual 
situation (ie, whether they were considered stable so in 
need of standard support, or in need of enhanced 
support).
Adolescents with a viral load of less than 1000 copies 
per µL or a most recent (and within the past 6 months) 
CD4 count of at least 200 cells per µL, or both, and 
recorded attendance at all scheduled clinic visits in the 
past 3 months were offered Zvandiri standard care (ie, a 
home visit once a month, plus a weekly, individualised 
text message). The text message was sent by the com-
munity adolescent treatment supporters and focused on 
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motivational reminders related to adherence, atten dance 
at clinic and support groups, and encouragement to 
contact the community adolescent treatment sup porters 
if any problems arose. An additional home visit was done 
if an adolescent missed a scheduled clinic appointment 
or support group meeting.
Adolescents with a viral load of at least 1000 copies 
per µL or CD4 count of less than 200 cells per µL, or 
both, who were at risk of common mental disorders or a 
major depressive disorder, had not attended one or 
more scheduled clinic visits in the past 3 months, had 
started ART in the past 3 months, who were preg nant, 
or had other psychosocial challenges or protection 
issues were offered Zvandiri enhanced care. This care 
involved two home visits a week, plus weekly phone 
calls and daily text messages. During the home visit, the 
community adolescent treatment supporters did an 
adherence assessment and gave adherence counselling, 
as appropriate. A community health nurse or case care 
worker, or both, accompanied the community adolescent 
treatment supporters where possible. If adolescents 
required more than two home visits a week (owing to 
child protection needs, depression, or ill health), the 
third visit (and onwards) of the week was done by 
community adolescent treatment supporters with the 
caregiver present.
Adolescents were allocated to the appropriate interven-
tion level (standard or enhanced care) at enrolment and 
reassessed every 3 months by community adolescent 
treatment supporters in conjunction with clinic nurses. 
Adolescents were moved between levels of intervention 
support as indicated by clinic attendance and other clinical 
or psychosocial factors (table 1). All participants in the 
Zvandiri intervention group were invited to a monthly 
support group, facilitated by a support group leader (a 
volunteer nurse, teacher, or social worker) in conjunction 
with the community adolescent treatment supporters, 
with supervision from the Zvandiri mentor. A standard-
ised curriculum was used, focusing on improving health 
and treatment literacy, HIV disclosure, resilience and 
coping strategies, sexual and reproductive health, social 
networks, and awareness of, and linkages to, services as 
required. Adolescents identified as being at risk of harm 
were immediately referred to the Zvandiri Intervention 
Coordinator or clinic nurse for mental health services or 
management with the Department of Social Services, or 
both.
Caregivers of adolescents in the Zvandiri intervention 
group were invited to a 12-session caregiver support 
group, facilitated by the Zvandiri mentor and community 
adolescent treatment supporters. Sessions were in Shona, 
the beneficiaries’ language, and focused on improving 
caregivers’ knowledge, skills, and confidence of HIV and 
treatment literacy, communication and parenting, and 
available support services. Sessions were planned to be 
held each month, with each session lasting up to 2 h.
Process evaluation
As part of a process evaluation of the Zvandiri inter-
vention, we did in-depth interviews between June 1, 2017, 
and Dec 21, 2018, with 54 trial participants (32 female 
partici pants, 22 male participants), 34 care givers 
(24 women, ten men), 15 health-care workers (13 women, 
two men), nine support group leaders (three women, 
six men), and 18 community adolescent treatment 
supporters (six female supporters, 12 male supporters). 
We observed 11 support groups meetings, 18 community 
adolescent treatment supporters’ coordination meetings, 
and eight caregiver information sessions. We sought to 
understand from multiple perspectives the context of 
young people’s lives (including the community 
adolescent treatment supporters), their experiences, and 
their support needs. Iterative qualitative data collection 
and analysis informed a grounded thematic analytical 
approach.
Cost analysis
We used standard costing guidelines18 to estimate the 
annual cost per adolescent treated on ART and cost 
per adolescent virally suppressed on ART through the 
Zvandiri intervention and control clinics. Cost estimates 
included staff salaries and training, drugs and other 
consumables, equipment, and overheads. We also did a 
sensitivity analysis of scenarios in which salaries were 
public sector-based, start-up costs were excluded, and 
the two Zvandiri mentors supervised the total number of 
Control group Standard Zvandiri intervention support Enhanced Zvandiri intervention support
Eligibility 
criteria
All eligible A viral load of <1000 copies per µL in the 
past 6 months; CD4 count ≥200 cells 
per µL in the past 6 months; attending all 
scheduled clinic visits in the past 
3 months; psychologically stable; and safe
Commencing ART or switching regimens in the past 3 months; 
a viral load of ≥1000 copies per µL in the past 6 months; CD4 count 
<200 cells per µL in the past 6 months; pregnant or breastfeeding; 
failing to attend at least one scheduled clinic visit in the past 
3 months; psychologically distressed; and abused or neglected
Intervention Adherence support provided by adult counsellors and nursing 
staff; after ART initiation, participants seen every 3 months, 
with CD4 monitoring at 6 monthly intervals; and prescription 
refills, pill counts and consultations with clinical staff used to 
measure adherence
Monthly support group; monthly home 
visit; weekly text message reminder; 
clinic contact; and caregiver workshop
Monthly support group; two home visits a week; daily text 
message reminder; weekly phone calls; clinic contact; caregiver 
workshop; referral and linkages; and community outreach visits 
with other community cadres
ART=antiretroviral therapy.
Table 1: Intervention components and levels of intervention support
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clinics within their two districts, rather than just the 
eight per district in our trial. A full description of the 
costing methods is listed in the appendix (pp 28–29).
Outcomes
The primary outcome, assessed in the modified intention-
to-treat population (ie, excluding enrolled participants 
who were later found to be HIV-negative), was the 
proportion of participants who had died or had virological 
failure (defined by an HIV-1 viral load of ≥1000 copies 
per µL at 96 weeks [window period for inclusion: 
88–104 weeks]) after enrolment. HIV viral load was 
assessed using blood spot samples, which were air 
dried on filter papers and stored at room temperature 
until they were taken every week to the Flowcytometry 
Laboratory (Harare, Zimbabwe). Viral load testing of 
HIV1 RNA was done via PCR using the NucliSENS EasyQ 
Director (bioMerieux; Marcy L’Etoile, France).
The five secondary outcomes were the proportion of 
partici pants who were not retained in clinic services, 
stratified according to the WHO definition of retention 
in HIV care;19 who had discontinued ART (defined as 
completely stopping taking drugs for at least 3 months), 
as documented in clinic records; who had depression, 
Figure 1: Trial profile
*Includes one participant who was not seen at midline. †Includes nine participants who were not seen at midline. ‡Includes one participant who was seen outside of 
the window period at midline. §Includes 24 participants who were not seen at midline. 
33 clinics assessed for eligibility
 16 clinics randomly assigned
 608 potential trial participants
17 clinics excluded  
 11 <20 adolescents with HIV in registers  
 6 private   
265 adolescents with HIV identified and approached 
8 clinics allocated to the Zvandiri intervention group
213 enrolled 
52 excluded
 35 refused enrolment
 17 did not meet inclusion criteria
190 assessed at midline (42–60 weeks) 
22 not assessed
 11 died
 7 seen outside window period
 4 not seen
1 HIV-negative 3 HIV-negative
192 assessed at endline (96 weeks)† 
212 included in primary endpoint analysis
8 not assessed
 6 died*
 2 lost to follow-up
 
343 adolescents with HIV identified and approached
8 clinics allocated to the control group
287 enrolled 
56 excluded
 42 refused enrolment
 14 did not meet inclusion criteria
 
 
244 assessed at midline (42–60 weeks)
40 not assessed
 21 seen outside window period
 13 not seen
 6 died
259 assessed at endline (96 weeks)§
284 included in primary endpoint analysis
11 not assessed
 5 died*
 4 lost to follow-up
 2 seen outside window period‡
See Online for appendix
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defined as scoring at least 10 out of 27 on the Patient 
Health Questionnaire (PHQ-9);20 who were at risk of 
common mental disorders (depression, anxiety, or 
both), defined as scoring at least 8 out of 14 on the 
Shona Symptom Questionnaire (SSQ-14);21 and who had 
poor quality of life, as measured on the European 
Quality of Life-5 Dimensions (EQ-5D) scale (which has 
been previously validated in Zimbabwe).22 Secondary 
outcomes were assessed at midline (42–60 weeks) and 
endline (96 weeks) in the modified intention-to-treat 
population.
Two exploratory outcomes were the proportion of 
participants with onward HIV status disclosure and with 
perceived stigma measured using the HIV/AIDS Stigma 
Instrument-People living with AIDS (HASI-P).23
Severe adverse events (deaths and admissions to 
hospital) were recorded and reported by type and study 
group. For all deaths, we used verbal autopsy to 
determine cause of death. Other, non-severe, adverse 
events were reported similiarly.
Statistical analysis
In 16 clusters, the sample size of 500 participants 
provided 80% power to detect a difference in detectable 
viral load of 35% among participants in the standard 
care group versus 18% in the Zvandiri intervention 
group, assuming 20% loss to follow-up and a coefficient 
of variation (k) between clusters of 0·25, using the 
sample size formula for cluster randomised trials as 
outlined by Hayes and Moulton.24 For secondary 
outcomes, the trial had 90% power to detect, for 
example, a difference in non-complete attendance of 
26% in the standard care group versus 10% in the 
Zvandiri intervention group, and 80% power to detect 
a difference in mean SSQ-14 score of 7·4 (SD 3·74) in 
the control group and 4·8 (3·74) in the Zvandiri 
intervention group. Our alpha level was 0·05.
The primary analyses were done in a complete case 
manner in the modified-intention-to-treat population. 
Cluster-level summary measures were used owing to 
the small number of clusters per group.24 For binary 
outcomes, the effect was estimated by the prevalence 
Zvandiri group 
(n=212)
Control group 
(n=284)
Sex
Female 119 (56%) 138 (49%)
Male 93 (44%) 146 (51%)
Age group, years
13–14 81 (38%) 110 (39%)
15–16 59 (28%) 86 (30%)
17–19 72 (34%) 88 (31%)
Currently in school
No 133 (63%) 198 (70%)
Yes 79 (37%) 86 (30%)
Orphanhood status
Not orphan 36 (17%) 54 (19%)
Maternal 49 (23%) 56 (20%)
Paternal 38 (18%) 61 (21%)
Both 84 (40%) 108 (38%)
Data missing 5 (2%) 5 (2%)
Number of children in household
≤1 63 (30%) 77 (27%)
2 56 (26%) 72 (25%)
3 43 (20%) 54 (19%)
≥4 50 (24%) 81 (29%)
Caregiver attitude*
Positive 183 (86%) 232 (82%)
Negative 29 (14%) 52 (18%)
Disclosed HIV status
Yes 55 (30%) 81 (34%)
No or do not know 130 (70%) 159 (66%)
Data missing 27 (13%) 44 (15%)
Stigma
0–1 76 (36%) 85 (30%)
>1 136 (64%) 199 (70%)
Mean SSQ-14 score (SD) 3·99 (3·37) 4·73 (3·60)
SSQ-14 score
<8 174 (82%) 221 (78%)
≥8 38 (18%) 63 (22%)
Mean PHQ-9 score (SD) 3·15 (3·11) 3·77 (3·71)
PHQ-9 score
<8 191 (90%) 242 (85%)
≥8 21 (10%) 42 (15%)
HIV viral load
Undetectable 55 (26%) 86 (30%)
<1000 copies per µL 54 (25%) 69 (24%)
≥1000 copies per µL 103 (49%) 129 (45%)
(Table 2 continues in next column)
Zvandiri group 
(n=212)
Control group 
(n=284)
(Continued from previous column)
Duration on ART
Not on ART at enrolment 15 (7%) 16 (6%)
<2 years 55 (26%) 60 (21%)
2–3 years 52 (26%) 58 (20%)
4–7 years 75 (37%) 128 (45%)
≥8 years 6 (3%) 17 (6%)
Data missing 8 (4%) 6 (2%)
Median CD4 count at ART initiation 
(IQR)
281 (232–319) 307 (251–324)
Data are n (%) unless otherwise specified. *Assessed via a positive or negative 
response to each of the following: my caregiver spoke or speaks to me with a 
warm and friendly voice; my caregiver seemed or seems emotionally cold to me; 
my caregiver appeared or appears to understand my problems and worries; my 
caregiver enjoyed or enjoys talking things over with me; my caregiver made or 
makes me feel better when I am upset; my caregiver did not or does not talk to 
me when I was or am upset.
Table 2: Baseline characteristics, modified intention-to-treat population 
(n=496)
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ratio (PR). Stratum (district)-specific PRs were estimated 
as the ratio of the geometric mean prevalence between 
groups for each of the two strata, and the overall PR was 
estimated as the weighted average of these stratum-
specific PRs. An approximate variance for the log (mean 
prevalence) in each group was estimated from the 
residual mean square from a two-way analysis of variance 
of community log-prevalence on strata and group. For 
outcomes with zero events in at least one cluster,24 PR 
was estimated as the ratio of the arithmetic mean 
prevalence between groups, with variance estimated 
from analysis of variance of prevalence on strata and 
groups. A 95% CI for the PR was estimated from this 
variance using a stratified t test with 14 degrees of 
freedom. For continuous outcomes, the measure of 
effect was the mean difference between groups, analysed 
in an analogous method based on mean scores in each 
facility.
Secondary analyses examined effect modification by 
baseline viral load, age group, sex, duration on treatment, 
SSQ-14 score, and PHQ-9 score.25 Predefined analyses 
included adjustment for baseline viral load and other 
variables that were imbalanced at baseline. We did 
sensitivity analyses to investigate the effect of missing 
data by using multiple imputation, analysed using an 
individual level logistic regression model, allowing for 
within-cluster correlation using fixed effects.
We used STATA software (version 15.0; StatCorp, College 
Station, TX, USA) for all analyses. A data safety and 
monitoring board oversaw the study and was responsible 
for assessing data quality, protocol compliance (participants 
and investigators), and frequency of adverse events among 
participants. Details of protocol amendments are included 
in the appendix (p 9).
This trial is registered with the Pan African Clinical 
Trial Registry, number PACTR201609001767322.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
In July, 2016, we identified 33 clinics in the two trial 
districts. Of the 33 clinics, 11 were excluded from the trial 
because they served fewer than 20 adolescents with HIV 
and six were private clinics. The remaining 16 primary 
care clinics were randomly assigned (1:1) to deliver either 
standard of HIV care plus Zvandiri (the Zvandiri 
intervention group) or standard of HIV care only (the 
control group).
Between Aug 15, 2016, and March 31, 2017, 608 adoles-
cents (aged 13–19 years) with HIV from the 16 clinics were 
identified and approached. Of these, 77 (13%) refused 
enrolment and 31 (5%) were ineligible, leaving 500 (82%) 
enrolled into the trial. Four (<1%) of the 500 participants 
had their data excluded from final analyses after repeat 
testing using several assays showed that they were HIV 
negative. 212 adolescents were enrolled in the Zvandiri 
intervention group and 284 in the control group (figure 1).
At enrolment, the median age of participants was 
15 years (IQR 14–17), 52% of adoles cents were female, 
81% were orphans, 47% had a viral load of at least 
1000 copies per µL, and 68% had not disclosed their HIV 
status to anyone other than health-care staff or caregivers 
(table 2). There was some imbalance between groups at 
enrolment, with participants in the Zvandiri intervention 
group more likely to be female, older, not in school, with 
a more positive caregiver attitude, less likely to have 
experienced stigma or to have common mental disorders 
or depres sion, more likely to have an unsuppressed viral 
Zvandiri group Control group Unadjusted PR or mean 
difference (95% CI)
Adjusted PR or mean 
difference (95% CI)*
p value
Primary outcome
HIV viral load ≥1000 copies per µL or 
death
22% (52/209) 36% (97/270) 0·61 (0·38 to 0·97) 0·58 (0·36 to 0·94) 0·03
Secondary outcomes
Discontinuation of ART for ≥3 months† 7% 16/209) 11% (30/270) 0·64 (0·28 to 1·48) 0·68 (0·23 to 1·99) 0·45
Attended <80% of scheduled visits† 13% (28/207) 15% (39/269) 0·83 (0·38 to 1·82) 0·80 (0·32 to 2·02) 0·62
SSQ-14 score ≥8 27% (60/192) 35% (86/259) 0·79 (0·52 to 1·19) 0·86 (0·60 to 1·23) 0·35
PHQ-9 score ≥8† 10% (22/192) 16% (38/259) 0·69 (0·32 to 1·48) 0·80 (0·38 to 1·69) 0·53
Mean SSQ-14 score 5·42 (0·42) 5·90 (0·55) –0·48 (–2·06 to 1·10) –0·31 (–1·70 to 1·08) 0·64
Mean EQ-5D Index 0·91 (0·01) 0·92 (0·01) 0·00 (–0·04 to 0·03) –0·01 (–0·04 to 0·03) 0·65
Exploratory outcomes
No onward disclosure 62% (134/192) 65% (172/259) 0·96 (0·83 to 1·11) 1·00 (0·85 to 1·18) 0·98
HASI-P stigma index >1 43% (90/192) 43% (119/259) 0·99 (0·79 to 1·22) 1·06 (0·85 to 1·31) 0·56
Data are % (n/N) or mean (SE). % refers to geometric mean of the cluster-level proportions. ART=antiretroviral therapy. EQ-5D=European Quality of Life-5 Dimensions. 
HASI-P=HIV/AIDS Stigma Instrument-People living with AIDS. PHQ= Patient Health Questionnaire. PR=prevalence ratio. SSQ=Shona Symptom Questionnaire. *Adjusted for 
district, age, sex, being in school, baseline viral load, and baseline SSQ-14 plus PHQ-9 scores. †Estimated using arithmetic means owing to at least one cluster with zero outcomes.
Table 3: Effect of the intervention at endline (96 weeks), modified intention-to-treat population (n=496)
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load, and with a shorter duration on ART. Age, sex, being 
in school, baseline viral load, and baseline SSQ-14 and 
PHQ-9 scores were adjusted for in all subsequent 
analyses.
Of the 496 eligible participants enrolled, 479 (97%) had 
primary outcome data at endline, including 
28 participants who died (17 in the Zvandiri intervention 
group, 11 in the control group). 14 (5%) participants 
in the control group and three (1%) in the Zvandiri 
intervention group did not complete 96 weeks of 
follow-up within the 8-week assessment period (ie, 
88–104 weeks). Process evaluation data suggested that 
two of the three participants in the Zvandiri intervention 
group who were lost to follow-up had relocated but 
continued to receive HIV care. The other participant, 
who had not disclosed her HIV status to her partner, 
discontinued the study owing to fear of unintentional 
disclosure.
Virological failure or death at endline was less common 
in the Zvandiri intervention group than in the control 
group (adjusted PR 0·58, 95% CI 0·36–0·94; p=0·03; 
table 3, figure 2). The Zvandiri intervention had a 
favourable effect on all secondary outcomes at endline, 
but the differences were not significant. The exploratory 
outcomes did not differ between the two groups (table 3).
There was some evidence of an intervention effect 
on the primary outcome at midline (adjusted PR 0·84, 
95% CI 0·64–1·10; p=0·17); the effect was stronger (0·80, 
0·64–1·03; p=0·07) when deaths in the first 3 months 
after enrolment were excluded (specified as a sensitivity 
analysis in the analysis plan; table 4). There was also 
some evidence of an intervention effect on PHQ-9 score 
at midline (adjusted PR 0·55, 95% CI 0·30–1·03; 
p=0·06), but not on other secondary outcomes (table 4). 
There were stronger intervention effects at 96 weeks 
in participants aged 13–16 years than in those aged 
17–19 years, although the effect modification was not 
significant (table 5). The results for the multiple 
imputation analysis were similar to the complete case 
analysis (adjusted PR 0·66, 95% CI 0·51–0·85; p=0·001; 
data not shown). The coefficient of variation was k=0·24 
for the Zvandiri intervention group and k=0·35 for the 
control group. Adjusted risk differences and the effects 
on viral load and death separately are shown in the 
appendix (pp 26–27).
Process evaluation data suggested that the Zvandiri 
intervention improved the quality of adolescents’ lives 
through a focus on shared experiences, role modelling, 
and supportive friendship (community adolescent treat-
ment supporters’ visits and support group). Their own 
and their caregivers’ HIV and treatment literacy was also 
improved (via support groups, community adolescent 
treatment supporters’ visits, and caregiver workshops) 
which, in tandem, enabled adolescents to better manage 
adherence and build their self-esteem. Adolescents with 
HIV described the transformative effect of a more 
Figure 2: Proportion of patients reaching the primary outcome during 
follow-up
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Zvandiri group Control group Unadjusted PR or mean 
difference (95% CI)
Adjusted PR or mean 
difference (95% CI)
p value
Primary outcome
HIV viral load of ≥1000 copies per µL or death 32% (68/201) 38% (98/250) 0·86 (0·66 to 1·11) 0·84 (0·64 to 1·10) 0·17
HIV viral load of ≥1000 copies per µL or death* 31% (65/198) 37% (97/249) 0·83 (0·65 to 1·05) 0·80 (0·64 to 1·03) 0·07
Secondary outcomes
SSQ-14 score ≥8 33% (70/190) 41% (98/244) 0·82 (0·54 to 1·24) 0·90 (0·61 to 1·31) 0·52
PHQ-9 score ≥8 11% (27/190) 23% (53/244) 0·48 (0·24 to 0·97) 0·55 (0·30 to 1·03) 0·06
Mean SSQ-14 score 6·08 (0·34) 6·91 (0·74) –0·82 (–2·58 to 0·93) –0·71 (–2·13 to 0·72) 0·30
Mean EQ-5D Index 0·86 (0·01) 0·84 (0·02) 0·02 (–0·02 to 0·07) 0·02 (–0·02 to 0·06) 0·27
Exploratory outcomes
No onward disclosure 61% (126/190) 66% (162/244) 0·93 (0·78 to 1·11) 1·00 (0·88 to 1·14) 0·99
HASI-P stigma index >1 55% (111/190) 62% (152/244) 0·89 (0·70 to 1·12) 0·92 (0·74 to 1·16) 0·44
Data are % (n/N) or mean (SE). % refers to geometric mean of the cluster-level proportions. EQ-5D=European Quality of Life-5 Dimensions. HASI-P=HIV/AIDS Stigma 
Instrument-People living with AIDS. PHQ=Patient Health Questionnaire. PR=prevalence ratio. SSQ=Shona Symptom Questionnaire. *Excluding four deaths in the first 3 months.
Table 4: Effect of the intervention at midline (42–60 weeks), modified intention-to-treat population (n=496)
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sympathetic household environment, where caregivers, 
benefitting from the workshops, were better educated 
about the low transmission risk of HIV in ordinary daily 
activities and were more responsive in meeting the 
nutritional and physical needs of adoles cents with HIV. 
These changes were experienced by adolescents with 
HIV as being better cared for and more cared about. 
Adolescents described the Zvandiri intervention as a way 
of relieving their sense of isolation and reducing their 
fear of the present and future implications of their HIV 
status. Community adolescent treatment supporters 
were hosted within local clinics and, over time, this 
situation influenced the attitudes of health-care workers 
towards adolescents with HIV, which was reported by 
health-care workers, community adolescent treatment 
supporters, adolescents with HIV, and caregivers to 
create a more open and receptive environment in which 
to seek care and support. The text messages, alongside 
the other support provided by the community adolescent 
treatment supporters, pro vided practical reminders that 
improved the capacity of adolescents with HIV to 
habituate treatment adherence.
The total annual cost per adolescent treated with ART 
was US$997·00 through the Zvandiri intervention clinics 
and $163·17 through control clinics (table 6). The annual 
cost per virally suppressed adoles cent on ART was 
$1340·00 for the Zvandiri intervention clinics and 
$450·36 for the control clinics. Across all clinics, personnel 
costs accounted for the largest proportion of the total cost.
Our predefined sensitivity analyses, which assessed 
scenarios where salaries were public sector-based, start-
up costs were excluded, and the two Zvandiri mentors 
supervised more clinics located within their two districts 
(22 for Bindura and 16 for Shamva) than the eight in our 
trial (thus taking the programme to scale across the 
district), showed that costs were reduced to $602·85 per 
adolescent treated with ART and $810·00 per virally 
suppressed adolescent (appendix p 29). Other input 
parameters, such as discount rate, life of vehicles and 
equipment, prices of supplies, and building utilities, had 
little effect on cost (appendix pp 28–29).
Regarding severe adverse events, there were 28 deaths 
(17 in the Zvandiri intervention group, 11 in the control 
group) and 57 admissions to hospital (20 in the Zvandiri 
intervention group, 37 in the control group). We did not 
collect robust data on non-severe adverse events. Verbal 
autopsy findings suggested that six (35%) of 17 deaths in 
the Zvandiri intervention group and eight (73%) of 
11 deaths in control group were due to cessation of ART 
sanctioned by caregivers and were probably motivated by 
faith healing. No adverse events were judged by the 
Medical Research Council of Zimbabwe or data safety 
and monitoring board to be related to study procedures.
Discussion
This cluster-randomised trial of adolescents with HIV in 
Zimbabwe found 42% lower prevalence of virological 
failure or death at 96 weeks among participants receiving 
enhanced ART adherence support through the Zvandiri 
programme than among those solely receiving standard 
Zvandiri group Control group Adjusted PR 
(95% CI)
p value pinteraction
Baseline viral load
<1000 copies per µL 10% (11/108) 12% (18/146) 0·57 (0·23–1·42) 0·20 0·61
≥1000 copies per µL 35% (41/101) 67% (79/124) 0·56 (0·39–0·82) 0·01 ··
Sex
Female 22% (24/118) 33% (41/129) 0·69 (0·39–1·22) 0·18 0·83
Male 31% (28/91) 39% (56/141) 0·68 (0·48–0·97) 0·04 ··
Age, years
13–16 20% (31/139) 40% (69/187) 0·51 (0·29–0·90) 0·02 0·12
17–19 29% (21/70) 27% (28/83) 1·00 (0·45–2·21) 1·00 ··
Duration on antiretroviral therapy, years
<2 31% (3/21) 56% (17/39) 0·81 (0·37–1·79) 0·55 0·43
≥2 25% (35/134) 37% (73/196) 0·64 (0·45–0·93) 0·02 ··
Data are % (n/N) unless otherwise specified. % refers to geometric mean of the cluster-level proportions. 
PR=prevalence ratio. 
Table 5: Effect modification of selected baseline characteristics on the primary outcome at endline 
(96 weeks), modified intention-to-treat population (n=496)
Zvandiri intervention clinics Control clinics
Cost Percentage of 
total cost
Total cost Percentage of 
total cost
ART treatment costs
Capital costs
Buildings and storage $1223·43 1% $1223·43 2%
Equipment $1001·93 0% $1001·93 1%
Recurrent costs $1521·62 1% $1521·62 2%
Personnel $73 561·43 35% $73 561·43 94%
Drug supplies $603·65 0% $603·65 1%
Lab supplies $1223·43 1% $1223·43 2%
Zvandiri intervention costs
Capital costs
Equipment $2967·96 1% ·· ··
Vehicles $3062·81 1% ·· ··
Recurrent costs
Personnel $62 933·93 30% ·· ··
Materials and supplies $2364·00 1% ·· ··
Vehicle operation $7660·44 4% ·· ··
Building operations $9024·24 4% ·· ··
CATS coordination and training $44 442·28 21% ·· ··
Total annual cost $210 367·71 100% $77 912·05 100%
Adolescents on ART, n 211 ·· 285 ··
Virally suppressed adolescents, n* 157 ·· 173 ··
Annual cost per adolescent treated on ART $997·00 ·· $163·17 ··
Cost per adolescent virally suppressed on 
ART
$1340·00 ·· $450·36 ··
Data are US$ unless otherwise specified. ART=antiretroviral therapy. CATS=community adolescent treatment 
supporters. *Includes only those known to be virally suppressed at 96 weeks. 
Table 6: Health provider costs of HIV treatment
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HIV care at rural clinics. This finding reinforces previous 
assertions that ambitious approaches such as the treat all 
strategy need to be complemented by interventions that 
actively support adherence to treatment and wellbeing 
more generally.3
To our knowledge, this trial is the first youth-led 
investigation of a multicomponent differentiated service 
delivery intervention focusing on adolescents’ HIV-
related and psychosocial outcomes. Only two other 
trials3,26 have shown an intervention’s effect on virol-
ogical outcomes among populations living with HIV 
in low-income and middle-income countries in general 
and adolescents with HIV, specifically. Both previous 
trials had a singular focus: structured adherence support 
to caregivers of adolescents with HIV3 and savings-led 
economic empowerment of adolescents with HIV.26 
An important explanation for the Zvandiri interven-
tion’s success was the multicomponent aspect, which 
addressed the inhibiting context in which adolescents 
with HIV navigated adherence, by providing them with a 
supportive peer network and a more receptive household 
environment. Consequently, adolescents with HIV 
receiving the Zvandiri intervention were able to benefit 
from continual support to drive and sustain behaviour 
change. The effectiveness of this comprehensive 
wraparound programme is in line with the so-called 
development accelerators approach advocated in the 
2019 UNAIDS Global AIDS update.27 Modelling clearly 
shows the synergistic effect of combining three 
development accelerators (support for parenting, cash 
transfers, and safe schools) on the lives of adolescents 
with HIV.27,28 Notably, the stronger intervention effects 
we report in 13−16 year-olds than in 17–19 year-olds 
are consistent with the observed trend of suboptimal 
adherence as adolescents age and become independent 
from caregiver supervision.2,29
Our trial highlights the importance of the context 
in which interventions, especially those in children 
and young people, are implemented. Implementation of 
inter ventions in contexts characterised by high youth 
unemployment, a struggling economy, persistent HIV 
stigma, considerable faith healing, and a struggling 
health-care system with weak mental health provision is 
particularly difficult. We found that ART adherence was 
sometimes disrupted when caregivers, acting upon faith 
healers’ instruc tions, ordered adolescents with HIV to 
temporarily or permanently stop their medication intake, 
often leading to clinical AIDS events or death. Given the 
high preva lence of faith healing and continued impact on 
ART adherence in sub-Saharan Africa,30 interventions 
need to continue targeting caregivers but also target faith 
healers. Further, although studies have shown that text 
mes saging can support ART adherence,31 its effectiveness 
is context-dependent. The rural setting of this trial 
resulted in electricity and mobile network challenges, 
meaning that text messages were not always sent. 
Additionally, community adolescent treatment supporters 
had to use coded messages specific to each adolescent 
with HIV to counteract the possibility of messages being 
intercepted and resulting in unintentional disclosure. 
Although burdensome, this aspect reinforced the 
differentiated aspect of the Zvandiri programme.
The high proportion (68%) of non-disclosure of HIV 
status seen in our questionnaire data is consistent with 
previous findings29,32 and process evaluation data, wherein 
adolescents with HIV mentioned that the consequences of 
disclosure include rejection. Given the potential individual 
and public health benefits associated with onward 
disclosure, including ART adherence and reduced levels of 
unprotected sexual activity,33 interventions should 
encourage and empower individuals with HIV to disclose 
their HIV status, espe cially to their sexual partners. The 
undetectable equals untransmittable concept (known as 
U=U), which signifies that HIV positive individuals who 
receive ART and have achieved and maintained an 
undetectable viral load cannot sexually transmit the virus 
to others,34 should be properly explained to the adolescents 
and their caregivers to enhance disclosure, sustained 
adherence, and acceptance of those with HIV.
Our cost analysis suggests that incorporation of the 
Zvandiri intervention into current standard of care would 
increase the cost of providing HIV treatment to 
adolescents by about three times. Most of this additional 
cost is due to the additional staff needed to deliver the 
counselling and adherence support at the clinics and in 
the community. In our study, each Zvandiri inter vention 
health facility had three additional staff who could provide 
the same level of care to many more adolescents than 
the 30 or fewer adolescents accessing treatment at each 
facility during the study period (as currently happens 
programmatically). Potential economies of scale, and 
therefore lower unit costs, could be achieved through 
provision of both ART and the Zvandiri intervention to 
larger numbers of adolescents. Costs were lower when 
assessed in an anticipated national scale-up scenario 
where salaries were public sector-based, start-up costs 
were excluded, and the two mentors supervised more 
clinics located within their two districts (22 for Bindura 
and 16 for Shamva) than the eight in our trial. Funders 
and policy makers might need to invest in these higher 
costs to avert the health and economic consequences of 
not achieving viral suppression in a population with the 
worst HIV outcomes, which will probably require many 
years of ART. A full economic analysis incorporating 
these long-term health and economic effects is under way 
to explore cost-effectiveness.
A major strength of this trial is that it evaluated the 
Zvandiri programme as delivered in a real-world and 
resource-constrained setting. The Zvandiri intervention 
can, therefore, be feasibly implemented in similar 
settings. In fact, the Zvandiri intervention has now (as of 
October, 2019) been introduced in the control group of 
this trial and continues to be used in the communities of 
the intervention group. In October, 2019, the programme 
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was scaled up in partnership with the Ministries of 
Health in six countries in sub-Saharan Africa (Eswatini, 
Mozambique, Nigeria, Rwanda, Tanzania, and Uganda), 
and now supports 961 community adolescent treatment 
supporters work ing with 65 500 beneficiaries in 
613 clinics. The finding that the Zvandiri intervention 
reduces rates of treatment failure strengthens support for 
further scale-up across the region. The results will likely 
inform policies and standard of care for young people 
with HIV in Zimbabwe, regionally, and internationally. 
Further, despite high rates of orphanhood (81%) and 
associated changes in households or locations, our trial 
had high follow-up (97%), providing a high level of 
confidence in the results and greater power than 
anticipated to detect differences in outcomes. Moreover, 
we used rigorous procedures to ascertain objectively 
measured outcomes; the cluster-randomised controlled 
trial was comple mented by process evaluation including 
in-depth qualitative data collection to understand the 
mechanisms of action.
This trial has a few limitations, including that it was 
difficult to deliver certain intervention components as 
intended. In addition to text messaging challenges, com-
munity adolescent treatment supporters were unable to 
visit some adolescents’ homes—a recurring issue in 
community-based interventions.35 Community adoles-
cent treatment supporters were, however, able to meet 
study participants in neutral spaces, highlighting the 
value of differentiated service delivery in responding 
to beneficiaries’ preferences.14 Finally, although process 
evaluation data suggested the mechanisms of effect of 
the Zvandiri intervention, it is possible that unmeasured 
or unassessed variables might also have played a role in 
the intervention effect.
In our trial, community adolescent treatment sup-
porters were well-supported, including by mentors located 
in the study districts. If taken to scale, Zvandiri mentors 
could support more community adolescent treatment 
supporters than they did in this trial. Additionally, each 
community adolescent treatment supporter supported a 
manageable number of adolescents with HIV (up to ten). 
In non-trial settings, community adolescent treatment 
supporters support up to 80 adolescents with HIV as a 
result of financial constraints. Future research should 
explore the effectiveness of community adolescent 
treatment sup porters when they support relatively large 
numbers of adolescents with HIV, and how this situation 
affects the total costs of delivering HIV treatment. How 
pro grammes for orphaned and vulnerable children could 
be strengthened should also be investigated to ensure 
they are community-based and holistic to support 
adolescents with HIV and their caregivers with a 
comprehensive package of services.
Our study is the only youth-led trial so far to show 
effectiveness of a community-based intervention in 
improving viral suppression among adolescents with 
HIV—a group with disproportionately poor HIV 
treatment outcomes.3−5 By showing that the sum of a 
multicomponent differentiated service delivery model is 
more important than the individual components, our 
study adds to the growing body of evidence to support 
WHO’s recommendations for community-based inter-
ventions to support ART adherence and retention in 
care. Our findings provide further justification for the 
scaling up of the Zvandiri intervention in sub-Saharan 
Africa. Community-based interventions are likely to 
make a substantial contribution to the UNAIDS 90-90-90 
targets if they offer differentiated services, are youth-led, 
and are multicomponent.
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